4//SEC Filing
Bisker-Leib Vered 4
Accession 0001171843-22-007662
CIK 0001738021other
Filed
Nov 24, 7:00 PM ET
Accepted
Nov 25, 4:41 PM ET
Size
8.7 KB
Accession
0001171843-22-007662
Insider Transaction Report
Form 4
Bisker-Leib Vered
Chief Operating Officer
Transactions
- Sale
Common Stock
2022-11-23$4.30/sh−9,569$41,147→ 1,060,416 total - Sale
Common Stock
2022-11-22$4.19/sh−14,929$62,553→ 1,069,985 total - Sale
Common Stock
2022-11-25$4.36/sh−2$9→ 1,060,414 total
Footnotes (2)
- [F1]The sales reported on this Form represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales are included in the Reporting Person's award agreement which allows the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction.
- [F2]The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $4.10 to $4.30 per share on November 22, 2022 and $4.15 to $4.43 on November 23, 2022. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above.
Documents
Issuer
Compass Therapeutics, Inc.
CIK 0001738021
Entity typeother
Related Parties
1- filerCIK 0001814093
Filing Metadata
- Form type
- 4
- Filed
- Nov 24, 7:00 PM ET
- Accepted
- Nov 25, 4:41 PM ET
- Size
- 8.7 KB